HER2-directed solid tumour research
Daiichi Sankyo Inc. funds a broad portfolio in HER2-positive, HER2-low, and HER2-expressing cancers, with work spanning breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma, endometrial cancer, and ovarian cancer. Its studies also include treatment settings for metastatic solid tumors and locally advanced disease.
- Trastuzumab deruxtecan in HER2-positive breast and gastric cancers
- HER2-low and HER2 IHC 0 breast cancer
- HER2-expressing ovarian and endometrial cancers
The sponsor also supports studies in adjuvant breast cancer and other HER2-driven malignancies across multiple tumour types.
Lung cancer and thoracic oncology
The company maintains a strong focus on non-small cell lung cancer and small cell lung cancer, including disease defined by EGFR mutations, HER2 overexpression, and actionable genomic alterations. Research also extends to first-line, previously treated, and metastatic thoracic disease.
- NSCLC with EGFR-mutated disease
- HER2-overexpressing NSCLC
- Extensive-stage and relapsed SCLC
Its portfolio includes both targeted therapy and antibody-drug conjugate approaches for advanced thoracic malignancies.
Hematologic malignancies
Daiichi Sankyo Inc. is active in acute myeloid leukemia, peripheral T-cell lymphoma, and broader hematological malignancies. The research landscape includes both newly diagnosed and relapsed/refractory blood cancers, with attention to pediatric, adolescent, and adult populations.
- Acute myeloid leukemia
- Relapsed/refractory peripheral T-cell lymphoma
- Hematological malignancies in diverse age groups
Studies in this area also cover FLT3-ITD-negative AML and treatment combinations used in leukemia care.
Genitourinary and gynecologic cancers
The sponsor supports trials in metastatic castration-resistant prostate cancer, urothelial carcinoma, renal cell carcinoma, and several gynecologic cancers, including ovarian, cervical, endometrial, and primary peritoneal cancer. These studies address both locally advanced and metastatic disease.
- Metastatic castration-resistant prostate cancer
- Urothelial carcinoma
- Platinum-resistant ovarian cancer
Its research also includes HER2-expressing ovarian cancer and advanced solid tumors with genitourinary involvement.
Pan-tumor and rare disease programs
Daiichi Sankyo Inc. funds pan-tumor studies across advanced solid tumors, including esophageal squamous cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, and biliary tract cancer. Its portfolio also includes work in Netherton syndrome.
- Advanced and metastatic solid tumors
- Esophageal squamous cell carcinoma
- Netherton syndrome
These programs reflect interest in both oncology and selected rare dermatologic disease areas.
